Inhibition of neovascularization using vegf-specific oligonucleotides
US5814620A · kind A · utility
129Cited by
0References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 12, 1995 |
| Grant date | Sep 29, 1998 |
| Priority date | — |
| Expiry date | Jul 12, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/53
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are methods of reducing neovascularization and of treating various disorders associated with neovascularization. These methods include administering to a tissue or subject a synthetic oligonucleotide specific for vascular endothelial growth factor nucleic acid effective in inhibiting the expression of vascular endothelial growth factor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.